A $2.3 million NIH grant will fund clinical advancement of the company's orphan-designated first-in-class CPT1 inhibitor targeting glioblastoma.
The notable strengths of this project include the high significance of developing new targeted approaches to tackle deadly glioblastoma.”— NIH Study Section Summary Statement
DENVER, CO, UNITED STATES, September 21, 2026 /EINPresswire.com/ — Numiera Therapeutics Inc. (“Numiera”), a pharmaceutical firm focused on creating innovative therapies for aggressive solid tumors, has announced receipt of a $2.3M NCI Direct-To-Phase II SBIR Grant. The funding will enable an early-stage clinical trial assessing the first-in-class CPT1 inhibitor etomoxir in glioblastoma (GBM) patients.
This initiative expands on earlier Phase I findings that provided initial dose safety data for the drug. Backed by this SBIR grant, the Numiera Therapeutics team intends to conduct a dose-escalation and window-of-opportunity study in individuals with recurrent glioblastoma. The trial has three primary objectives: determining the maximum tolerated dose within this neuro-oncology population, examining the drug’s pharmacology in surgically removed brain tumor tissue, and detecting an early efficacy signal. Favorable results are anticipated to open the door for subsequent later-stage trials.
The NIH assembled a panel of medical oncology specialists from across the U.S. to evaluate the proposed clinical study. Their summary statement read: “The notable strengths of this project include the high significance of developing new targeted approaches to tackle deadly glioblastoma, the innovation of targeting fatty acid oxidation in this cancer, the outstanding team with strong record of accomplishments in drug development and glioblastoma, and the clinical trial outlined in excellence with appropriate statistical design.”
Dr. Izi Stoll, Co-Founder and CEO of Numiera Therapeutics, commented: “The recent FDA approvals and billion-dollar transactions involving vorasidenib and dordaviprone in neuro oncology indications have shown that mitochondrial-targeting small-molecule drugs are a complete game-changer in the field. With an even broader mitochondrial target, orphan designation for all malignant gliomas, independent validation in five different preclinical models from five different laboratories, and promising Phase I safety data for our lead drug candidate, we believe our approach will have a significant impact in this space.”
About The Company:
Numiera Therapeutics is committed to leading the development of novel cancer therapeutics through metabolic targeting of tumor cells. Featuring an orphan-designated lead candidate and an expanding pipeline, the company’s mission is to revolutionize cancer patient care by crafting safer, more potent treatments aimed specifically at chemotherapy-resistant solid tumors. The Direct-To-Phase II SBIR Grant Award Number issued to Numiera Therapeutics, Inc. by the National Cancer Institute is 1R44CA310352-01.
Forward Looking Statements
To the extent statements contained in this news release are not descriptions of historical facts regarding Numiera Therapeutics Inc., they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995. Forward-looking statements can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or similar expressions that convey uncertainty of future events or outcomes. Any statement describing Numiera’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements which are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for interim or final results and data related to Numiera’s clinical and non-clinical trials, or third-party trials evaluating Numiera’s candidate products, the timing and plans with respect to enrollment of patients in Numiera’s clinical trials, the potential benefits of Numiera’s drug candidates, and Numiera’s strategy and plans with respect to its business and research programs. Such statements are based on Numiera’s expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks associated with clinical and preclinical trials and product development, the risk that interim data may not be reflective of final data, risks related to regulatory approvals, and risks related to the impact of global economic conditions. The company undertakes no obligation to publicly update any forward-looking statement, except as required under applicable law.
Anjali Hansen
Numiera Therapeutics
hansen@numiera.com
Visit us on social media:
LinkedIn
